Tissue engineering and regenerative medicine research - how can it contribute to fight future pandemics? by Caballero, David et al.
Tissue engineering and regenerative 
medicine research - how can it contribute 
to fight future pandemics?
https://doi.org/10.21814/uminho.ed.24.18
David Caballero 
David Caballero (ORCID: 0000-0001-7930-2535) is a biophysicist with an M.Sc. and 
a Ph.D. in Nanoscience from the University of Barcelona (Barcelona, Spain). Current-
ly, he is a research associate at the I3Bs (Research Institute on Biomaterials, Biode-
gradables and Biomimetics of University of Minho) and ICVS/3B’s (PT Government 
Associate Laboratory), working in the field of 3D tumor - and organ-on-chip based 
models for the study of tumor physiopathology. 
 
Mariana R. Carvalho 
Mariana R. Carvalho (ORCID: 0000-0003-2081-3909) has a Pharmacy background 
and PhD in the field of Tissue Engineering, Regenerative Medicine and Stem cells at 
the I3Bs (Research Institute on Biomaterials, Biodegradables and Biomimetics of Uni-
versity of Minho) and ICVS/3B’s (PT Government Associate Laboratory). She is  a 
postdoctoral fellow working in Tissue Engineered In Vitro Models on a Chip for Can-
cer Research under the project IET Harvey Research Prize 2017. 
 
Subhas C. Kundu 
Subhas C. Kundu (ORCID: 0000-0002-7170-2291) received his PhD in Genetics from 
Banaras Hindu University (India). His area of interest includes biomaterials for 3D can-
cer modeling and drug screening. Currently, he is an ERA Chair professor at the 3B´s 
Research Group (I3Bs - Research Institute on Biomaterials, Biodegradables and Biomi-
metics of University of Minho and ICVS/3B´s - PT Government Associate Laboratory 
of University of Minho). There he leads a multidisciplinary team fully dedicated in the 
development of a new generation of in vitro 3D tumor models for drug screening. 
Joaquim M. Oliveira 
Joaquim M. Oliveira (ORCID: 0000-0001-7052-8837) is a biochemist and principal 
investigator at the I3Bs (Research Institute on Biomaterials, Biodegradables and Bio-
mimetics of University of Minho) hired under the Prestigious Investigator FCT 2015 
Program. Over the years, he has focused his work on the field of tissue engineering, na-
nomedicine, stem cells, and cells/drug delivery. More recently, he set up a new research 
line at the ICVS/3B’s (PT Government Associate Laboratory of University of Minho) 
on 3D in vitro models of disease. 
 
Natália M. Alves 
Natália M. Alves (ORCID: 0000-0002-8741-4091) owns a PhD in Science and En-
gineering of Polymers by the School of Engineering of the University of Minho and 
is an Assistant Professor & Research Staff member at the I3Bs (Research Institute on 
Biomaterials, Biodegradables and Biomimetics of University of Minho and ICVS/3B’s 
- PT Government Associate Laboratory of University of Minho). She has been 
developing activities mainly related with smart and biomimetic polymers and biode-
gradable polymers from marine origin for biomedical applications. 
 
Rui L. Reis 
Rui Luis Reis, (ORCID: 0000-0002-4295-6129) PhD, DSc, Hon. Causa MD, Hon 
Causa PhD, FBSE, FTERM, member of NAE, FAIMBE, FEAMBES, is the Director 
of the 3B’s Research Group (I3Bs - Research Institute on Biomaterials, Biodegrada-
bles and Biomimetics of University of Minho) and of the ICVS/3B´s - PT Govern-
ment Associate Laboratory of University of Minho). He is also CEO of the European 
Institute of Excellence on Tissue Engineering and Regenerative Medicine, Coordinator 
of the Discoveries Centre for Regenerative and Precision Medicine, Global Past-Pres-
ident of the Tissue Engineering and Regenerative Medicine International Society and 
Editor-in-chief of the Journal of Tissue Engineering and Regenerative Medicine. He is 
a recognized world expert in the TERM and biomaterials fields.
391
A Universidade do Minho em tempos de pandemia (Re)Ações
ABSTRACT
 Understanding the pathogenesis of viral infection is of paramount importance 
for the development of better therapies. In the particular case of COVID-19, the mech-
anism of infection is highly complex and involves a critical cascade of events, which 
can lead to the death of the patient. Intense research is currently being performed to 
gain mechanistic insights about the virus etiology and to evaluate new therapeutic ap-
proaches. The development of point-of-care diagnostic tools, predictive drug screen-
ing platforms, and biomimetic models of the disease could play a key role in under-
standing the cellular and molecular mechanism of viral infection and its response to 
drugs. In this regard, specific tissue engineering and regenerative medicine approaches, 
such as microfluidics and organ-on-a-chip technologies, as well as bio printed in vitro 
disease models, could be used to develop a technological platform to fight COVID-19, 
and other virus pandemics yet to come. Herein, we briefly discuss about how such ap-
proaches can contribute to address current and future viral pandemics by highlighting 
recent successful examples. 
 
INTRODUCTION
 Virus infections continue to be a major health problem worldwide. During the 
last decade, three main viral outbreaks have affected the population: MERS, SARS-
CoV, and SARS-CoV-2. The latter virus causes the well-known COVID-19 disease, 
which was declared as world pandemics in March 2020 by the World Health Organi-
zation. This type of viral infections causes great expenditures to the governments and 
their national health systems. It is therefore vital to invest in groundbreaking technol-
ogies to gain mechanistic insights about the pathophysiology of the disease, which 
can lead to the development of better therapeutic solutions. In the particular case of 
COVID-19, solid evidences have shown that the infection is initiated when the SARS-
CoV-2 virus enters the lung. Therein, the spike (S) viral protein (N-terminal portion 
of the viral protein unit S1) specifically binds to the angiotensin-converting enzyme 2 
(ACE-2) receptor present on type II lung pneumocytes [1]. After infection, the virus 
is replicated initiating a critical cascade of events that, in severe cases, results in the 
death of the patient. The main two complications in COVID-19 responsible of this 
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dramatic end are: (i) severe pneumonitis, which causes the asphyxia of the patient and 
(ii) massive blot clotting, which can lead to serious thromboembolisms. Both of them 
are life-threatening situations, and therefore, their rapid diagnostics is vital for a better 
patient prognosis. However, one of the main problems with COVID-19, and other 
viral diseases, is how to address the fatal cytokine storm that involves multiple organs 
and tissues, such as the lung, the heart, the kidney, and the vasculature. Indeed, there 
are no well-defined treatments for this type of patients as the actuation guidelines are 
evolving in a daily basis.
 Current methods to investigate the etiology of pathologies, including viral in-
fections such as COVID-19, and their response to medication are obsolete. Typically, 
pharmaceutical and biotechnological companies use traditional in vitro and in vivo - 
animal - models to test drugs (Figure 1 A-B). The formers are based on standard tissue 
culture systems, such as Petri dishes or flasks. These methods have several advantages, 
such as high-throughput properties, low cost, or easy manipulation. However, they are 
also associated with serious drawbacks: cells are cultured in an artificial - flat - environ-
ment, and therefore, they show perturbed levels of gene expression. As a result, cells 
respond to drugs differently as they would do in the human body. In contrast, animal 
models show the needed biological, structural and rheological complexity similar to 
the native scenario. However, as widely acknowledged, these models are not predictive 
of the outcome of drugs in humans. In addition, they lack the human immune system, 
are critically controversial, and extremely expensive. Altogether, this limits our capacity 
to investigate the etiology of diseases. And importantly, this also makes that 80-90% 
of the drugs, which successfully reach the preclinical assay stage, to fail when tested in 
patients [2]. Therefore, there is the need for new point-of-care technologies and versa-
tile solutions that are clinically relevant and capable to improve our understanding on 
disease etiology, its diagnosis, and in the development and screening of drugs. In par-
ticular, these new technologies should be capable to: (i) describe the physiopathology 
of the disease while being at the same time compatible with standard laboratory tech-
nologies; (ii) mimic the native (human) scenario and (iii) be cost-effective, portable, 
high-throughput, clinically-relevant, highly-sensitive, and mass produced. 
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Microfluidics
 During the last decade, a new generation of point-of-care technologies have 
emerged for the development of biomimetic in vitro models of human organs/tissues 
and its diseases. These models are based on microfluidics technology, and bridge the 
large gap between the afore-mentioned traditional in vitro systems and complex animal 
models. Microfluidics is defined as “the science and technology of systems that process or 
manipulate small volumes (10-9 to 10-18 liters) of fluids, using channels with dimensions 
of tens to hundreds of micrometers” [3]. These channels are engrafted into “chips” of 
few centimeters in size, and are typically made of soft, biocompatible, and transparent 
materials (e.g., elastomers or hydrogels) (see Figure 1C). The channels are continuously 
perfused with fluid, such as culture media, plasma or whole blood, and recapitulate the 
architectures, physicochemical environments and interfaces on the native scenario. 
 Working with microfluidic devices is associated with several advantages com-
pared to traditional in vitro and in vivo systems. This includes an enhanced speed and 
control over the different parameters, a reduced consumption of samples and reagents, 
capability of parallelization, the possibility to integrate sensors (and other electric com-
ponents), or a higher efficiency, among others. In addition, the fabrication of micro-
fluidic devices employs the technology developed for the microelectronics industry, 
making their fabrication cost very low. Briefly, the fabrication of microfluidic devices 
uses UV photolithography, chemical etching, and soft lithography methods to repli-
cate a design from a mold using a biocompatible elastomeric material, such as poly-
dimethylsiloxane (PDMS). Other more sophisticated techniques, such as 3D printing, 
micromachining, xurography, or injection molding can also be used. In this case, other 
(bio)materials are employed, such as hydrogels (e.g., collagen, gelatin, acrylamide-bi-
sacrylamide, etc.) or polymers (e.g., polymethylmethacrylate, polystyrene, polycar-
bonate, etc.). The obtained resolution depends on the selected fabrication methods, 
but it is possible to fabricate structures from few mm to sub-mm resolutions. 
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Figure 1. Systems for disease modelling and drug screening. (A) In vitro models; (B) In vivo - animal - 
models; (C) Microfluidics device. (Image permissions: (A) Creative Commons Attribution 2.0 Generic;  
(B) National Institute of Health (US; Public domain); (C) Creative Commons Attribution 3.0 Unported).
 The integration of human cells within microfluidic devices reproducing the 
functional units of human organs or tissues results into organ-on-a-chip systems. These 
advanced microfluidic models recapitulate the properties of the native tissue or organ 
(e.g., cell content, extracellular matrix, mechanochemical properties, etc.) and dynamic 
functions (e.g., biochemical gradients, fluid flow, shear stress, etc.). In this sense, or-
gans-on-a-chip are considered as physiologically-relevant in vitro model platforms to 
study physio pathological processes, such as viral infections. They can also be utilized 
as powerful predictors of disease progression, drug efficacy, or for the identification of 
therapeutic targets or new disease biomarkers. Finally, the potential of organs-on-a-
chip devices as screening platforms is supported by the number of companies that have 
emerged during the last years dedicated to the development of this type of technology 
[4]. Altogether, the advanced capabilities of microfluidic and organ-on-a-chip technol-
ogy open unprecedented opportunities to gain key insights about the mechanism of 
virus infection and for assessing the efficacy of anti-viral drugs. Next, we will illustrate 
how microfluidics technology can contribute in managing the current and future virus 
outbreaks.
HOW CAN MICROFLUIDICS TECHNOLOGY HELP IN VIRUS PAN-
DEMICS?
 Microfluidics can significantly contribute in the current and future virus pan-
demic in three main scenarios: (i) by developing rapid and highly sensitive diagnosis 
TISSUE ENGINEERING AND REGENERATIVE...
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tools of viral infection; (ii) by improving the efficiency of anti-viral drug discovery and 
screening; and (iii) by developing clinically-relevant disease models to investigate the 
etiology of virus infection (Figure 2). In the following, we briefly describe these three 
different types of contributions.
 
Figure 2. Contribution of  microfluidics technology in virus pandemics. Three different main scenarios 
are identified, including diagnostics, screening, and disease modelling (ADME: administration, distribution, 
metabolism, and excretion).
Rapid diagnosis of viral infection
 The rapid diagnosis of viral infections is of paramount importance to acceler-
ate patient intervention and improve its prognosis. This is particularly true in viruses 
with high infection rates that can lead to patient death, such as COVID-19. The stand-
ard-of-actuation to diagnose (and quantify) this and other type of viruses is mainly 
based on real-time reverse transcription polymerase chain reaction (RT-PCR) that de-
tects the specific genetic material of the virus. Briefly, RT-PCR uses thermal cycles to 
amplify the amount of DNA molecules and a specific fluorescent dye to detect the 
targeted genetic material. Some viruses, such as the SARS-CoV-2 only contain RNA. 
Therefore, to be detected by RT-PCR it is first needed to convert the RNA to DNA. 
This is accomplished by a process denoted as ‘reverse transcription’. 
 The initial genetic material is gathered from samples taken from the upper 
respiratory tract in suspicious patients (nasopharyngeal swabs, oropharyngeal swabs, 
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nasopharyngeal washes, or nasal aspirates) (Figure 3) [5]. This method is very efficient 
and the results can be observed while the process is ongoing. However, RT-PCR can 
be time consuming (it can take several days to complete), laborious (well-trained 
personnel is required), and it typically requires the use of bulky and expensive equip-
ment. Other methods employed for the diagnosis of viral infection include the 
detection of antigens or antibodies in biological fluids by e.g., the traditional en-
zyme-linked immunosorbent assay (ELISA). However, this type of methods can lead 
to false results due to the low viral load or mutations in their genome. Considering 
that thousands of suspicious cases need to be efficiently tested in a daily basis, more 
efficient point-of-care technologies are needed for the rapid diagnosis of the viral 
infection, and in particular, for COVID-19.
 Microfluidic chips have been widely utilized for the detection of viruses in the 
recent years [6, 7]. These devices typically integrate miniaturized analytical systems 
that can store, transport and process fluids and reagents that enable the early and re-
liable diagnosis of the disease-causing virus. The chips also integrate interconnected 
microchannels, miniaturized mixers and valves, reaction chambers and/or detectors 
(i.e., biosensors) to manipulate the sample and all the fluids. Interestingly, they can 
be combined with PCR analysis to mimic the gold-standard laboratory RT-PCR 
workflow but at a higher speed and efficiency, using less reagents, and at a lower 
cost [8]. As an example of this approach, a portable microfluidic system was recently 
developed for the sensitive detection of Hepatitis C, HIV, Zika, and human papil-
loma virus by RT-PCR [9]. This work demonstrated the feasibility to perform viral 
detection on-chip and the possibility to perform the analysis at the point-of-need 
location without sending the sample (or the patient) to the hospital. Similarly, an 
integrated microfluidic device was also developed for the isolation, processing, am-
plification, and detection of genetic viral material by RT-PCR [10]. The device pre-
stored all the liquids and reagents needed for the reactions, which were manipulated 
by miniaturized pouches and valves. The chip was used to detect bacterial B. Cereus, 
viral armored RNA HIV, and HIV I virus in saliva. Again, the device included the 
RT-PCR chamber were the genetic material was amplified and detected in a fast and 
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efficient manner. Finally, nasopharyngeal aspirate/swaps, microfluidic processing, 
and PCR analysis were combined in a point-of-care single-use microfluidic device 
for the rapid, low cost, and accurate diagnosis of Influenza A virus (Figure 3) [11]. 
The chip integrated the solid phase extraction and molecular amplification via RT-
PCR to amplify the RNA of the virus using human nasopharyngeal aspirate and 
swap directly obtained from clinical specimens. The sample preparation channel was 
connected directly with the RT and PCR steps. Briefly, the assay was performed first 
mixing the aspirate/swaps from the specimen with a lysis buffer and injected in the 
preconditioned channel to release the virus nucleic acids. Next, this genetic material 
bound to the SPE column. After several cleaning steps and the injection of reaction 
buffers, the extracted RNA was amplified by the RT-PCR on-chip (first, RT cham-
ber and then PCR channel). The serpentine PCR channel was optimized to achieve 
repeatable and predictable temperature profiles flowing the sample through 30 cy-
cles of PCR. Interestingly, this approach showed a higher sensitivity than two rapid 
immunoassays traditionally used, and a high specificity equivalent to the one of rap-
id assays and direct fluorescent antigen testing. The obtained results were validated 
using standard bench-top quantitative RT-PCR and similar results were obtained. 
Finally, the simplicity and versatility of this approach allows the system to be applied 
to a wide variety of virus infection and other type of pathogens.
 Overall, these examples illustrate how microfluidics can accelerate the diag-
nostics of viruses and other pathogens. It also shows how the development of total-
ly-integrated microfluidic systems can contribute in reducing the need to perform in 
situ evaluations at the hospital. This would eventually reduce the number of unnec-
essary visits as well as the workload in the laboratories.
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Figure 3. Microfluidic device for the rapid diagnosis of  Influenza A RNA virus in human respirato-
ry specimens. (A) Experimental set-up showing two microfluidic chips with attached thin film heaters. (B) 
Channel design with three sections: sample preparation, RT chamber and PCR channel. (C) Scheme show-
ing the microfluidic assay process: the nasopharyngeal sample is mixed with lysis buffer and injected into the 
chip, where the PCR products are read using a commercial capillary electrophoresis system. Reproduced with 
permission from the publisher [11] (Creative Commons Attribution License).
Drug screening and discovery
 One of the main characteristics of COVID-19 and other viruses is its genetic 
diversity, which generates variants of the virus with mutations. This causes different 
susceptibilities on patients depending on the virus characteristics and it is associat-
ed with the resistance to anti-viral drugs. The continuous discovery and screening of 
drugs is therefore of great importance to ensure the quality and life expectancy of the 
population during the current and future virus outbreak. The gold standard to inves-
tigate the efficacy of anti-viral compounds in vitro focus on using static monolayers 
and large populations of infected cells. However, the efficacy of a drug at a particular 
dosage may differ and some individual cells may respond differently. This have impor-
tant implications for infection outcome and drug resistance. For this reason, it may be 
convenient to investigate individual infected cells. In this regard, microfluidic systems 
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have an enormous potential for the screening and discovery of anti-viral drugs on indi-
vidual cells due to its capability to encapsulate cells in micro-droplets. In addition, the 
integration of optical or electrochemical biosensors within microfluidic systems can 
be used to increase the sensitivity and limit of detection of key analytes related to viral 
infection or therapy efficacy. With this type of approach, it is possible to simultaneous-
ly observe a multitude of individual cells infected with viruses (or other pathogens), 
providing key insights about infection dynamics or drug efficiency. As an example, a 
high-throughput droplet-based microfluidic platform was employed to evaluate the 
efficacy of neutralizing antibodies for different variants of murine noroviruses using 
single virus particles incubated in a large number of pico-liter drops [12]. By identify-
ing both sensitive and resistant viruses, this device showed the capability to estimate 
the potential for viral resistance to anti-viral drugs prior to their clinical use. The ob-
tained results were validated by traditional assays, but at a lower cost and faster speed. 
Similarly, a microfluidic chip containing multiple micro-cavities was recently reported 
to assess the viral infection dynamics and inhibition on individual cells infected with 
enterovirus [13]. The chip was employed to investigate three classes of enterovirus in-
hibitors with distinct mechanisms of action. The main finding of this work was that 
the three compounds provided a different ´signature´ related to how the virus replicat-
ed. Therefore, by comparing on-chip the signature of a compound to those of known 
drugs, it would be possible to narrow down the target of the drug. Importantly, and 
similar to the former works, this device could be applied for the discovery and screen-
ing of any class of therapeutics.
 Finally, microfluidics can also significantly contribute in developing anti-viral 
vaccines. As an example, a recent study reported a microfluidic device to perform mil-
lions of parallelized single-virus multi droplet-based assays to screen different vaccine 
candidates to HIV-1. The viral particles were sorted according to the epitope expression 
recognized by broadly neutralizing antibodies with an impressive efficiency of >99% 
[14]. Actually, the device worked as a miniaturized flow cytometer enabling fluores-
cence-based sorting of viral particles possessing antigenic envelope proteins. Finally, a 
genomic analysis could be performed on the sorted virus particles that expressed anti-
body-binding epitopes. Overall, this work showed how microfluidic systems could be 
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used to screen in a high-throughput manner diverse virus library to reveal novel targets 
for virus vaccine.
 To sum up, the above-mentioned demonstrates how microfluidics can be ap-
plied for the development and screening of anti-viral drugs and vaccines, showing its 
potential to replace, or complement, the traditional methods currently used by phar-
maceutical and biotechnology companies [15]. This is particularly attractive due to 
their intrinsic properties, such as miniaturization and parallelization of experiments. 
This will univocally benefit the biomedical industry, which aims at using more clin-
ically-relevant models but at a lower cost and faster speed. In this regard, it is worth 
noting that microfluidic systems are currently being utilized by regulatory agencies, 
such as the US Drug and Food Administration, to assess the toxicology of food sup-
plements and additives [4]. And biotechnology and pharmaceutical companies, such 
as Pfizer™, Roche™, Merck™, or Johnson & Johnson™, among others, are also 
employing these systems to accelerate the screening and development of novel thera-
peutic agents [4]. Overall, the future looks promising for microfluidics in the field of 
diagnosis and drug development.
 
Disease modelling
 The combination of microfluidics, nanotechnology, biochemistry and cell biol-
ogy can also be employed to elucidate the mechanisms of viral infection in key organs 
and tissues of the human body, thus contributing to an improved understanding on 
disease etiology. Among all the events to investigate, the mechanism of host-virus pro-
teins interaction is a key factor. In the particular case of COVID-19, and as afore-men-
tioned, solid evidences have shown that the spike (S) viral protein of SARS-CoV-2 
virus specifically binds to the ACE-2 receptor on type II lung pneumocytes to infect 
the cell [1]. This initial interaction triggers a cascade of critical events that affect dif-
ferent organs and tissues, including the lung, the kidney, the heart, and the vascula-
ture. Therefore, its study may provide valuable insights into the biological functions 
of virus virulence and on the molecular basis of virus pathogenicity. In this regard, the 
recent advances in organ-on-a-chip technology may provide an opportunity for the 
development of realistic in vitro models of these organs and tissues. As an example, 
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the pneumonitis induced by SARS-CoV-2 can be investigated by means of a lung-on-
a-chip model; the severe cardiac implications with a heart-on-a-chip; the renal damage 
with a kidney-on-a-chip; and the massive blood clot formation by means of a vascula-
ture-on-a-chip. The development of these on-chip models will univocally contribute 
to: (i) a better understanding of the process of viral infection; (ii) the identification of 
new therapeutic targets and biomarkers and (iii) the evaluation of the efficacy of an-
ti-viral pharmacological compounds. In the following, we describe several examples on 
the development of these four different organs-on-a-chip models, which are associated 
not only with COVID-19 pandemic, but also in other important viral infections.
 
 • Lung-on-a-chip
 The field of organ-on-a-chip technology emerged after the development of the 
lung-on-a-chip model [16]. This model reconstituted the functional alveolar-capillary 
interface of a human lung by seeding inside the microfluidic chip bronchiolar epithe-
lial and microvascular endothelial cells. The chip contained two microchannels sepa-
rated by a porous membrane with both cells seeded on either side mimicking the alveo-
lar-capillary interface. Two additional lateral channels were employed to actuate on the 
membrane by mechanical cyclic stretching, which reproduced physiological breath-
ing. Importantly, this model was utilized to reproduce complex integrated organ-level 
responses to bacteria and inflammatory cytokines introduced into the alveolar space. 
In this regard, this work paved the way towards applications in the field of viral in-
fections, not only for gaining mechanistic insights, but also to evaluate the efficacy 
and toxicity of anti-viral compounds. Indeed, in a recent work, this model was used to 
reproduce the infection of the bronchiolar epithelium with H1N1 influenza A virus 
and, importantly, the emergence of drug resistance [17]. The chip was used to identify 
the molecular mediators of the host response to infection and to discover a potential 
new antiviral therapeutic that targeted these mediators. Altogether, this work showed 
how lung-on-a-chip technology can be applied to create a clinically-relevant model to 
study viral infections, representing a powerful pre-clinical tool for the development 
and screening of anti-viral compounds and vaccines [18].
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 Variations of this on-chip model have been also reported. As an example, a 
“breathing” alveolus-on-a-chip model was recently described mimicking the physio-
logical gas exchange using primary human lung alveolar cells (Figure 4). The model re-
produced the cyclic mechanical deformation produced by the diaphragm, and the air-
blood barrier and the air-liquid interface of the native alveoli. Interestingly, the model 
included both type I (ATI) and type II (ATII) pneumocytes as well as lung endothelial 
cells. As mentioned above, the latter cells (ATII) express the ACE-2 receptor where 
SARS-CoV-2 binds, and therefore, this model may be applied for the investigation of 
COVID-19 etiology. This model could also be used for evaluating the effect of viral 
infections on individuals suffering from chronic diseases, such as asthma or chronic 
obstructive pulmonary disease, who are considered as high risk patients [19]. 
 
 
Figure 4. Lung-on-a-chip.  (Top) Scheme showing the working procedure (contraction) of the lung and its 
functional unit - alveoli. The alveolar barrier is formed by a tight alveolar epithelial cell layer made of AT I 
and AT II cells together with endothelial cells (EC). (Bottom) Scheme showing the working procedure of the 
microfluidic alveoli model: medium exchange and breathing modes. The “breathing” is induced by applying 
cyclic vacuum. Two valves located on each sides are opened for medium exchange. (Right) Picture showing 
an array of individual lung-on-a-chip models. Reproduced with permission from the publisher [20] (Creative 
Commons Attribution 4.0 International License).
 
 • Heart-on-a-chip
 Besides attacking the lungs, COVID-19 also implies severe cardiovascular com-
plications, such as myocardial injury, myocarditis, acute myocardial infarction, heart 
403
A Universidade do Minho em tempos de pandemia (Re)Ações
TISSUE ENGINEERING AND REGENERATIVE...
failure, dysrhythmias, and venous thromboembolic events [21]. Indeed, these com-
plications can significantly contribute to the morbidity and mortality associated 
with this disease [22]. A recent study showed that about 30% of COVID-19 patients 
displayed myocardial injury and many other investigations have focused on the car-
diovascular complications associated with COVID-19 and other viral infections 
[23]. The mechanism of cardiovascular impairment is not well understood. How-
ever, some evidences suggest that a widespread systemic inflammation issues result-
ing from the generated cytokine storm, together with the direct viral infection of 
the cardiovascular system, and pre-existing morbidities, may be responsible of this 
COVID-19-induced heart damage [24]. The excess of cytokines can indeed lead to 
a fatal myocarditis and the virus can directly infect cardiac cells, which also express 
the ACE-2 receptor. Indeed, this direct viral infection was already observed in other 
virus outbreaks, such as SARS-CoV [25]. Importantly, some of the drugs that were 
tested to treat the virus, such as hydroxychloroquine and remdesivir, showed some 
degree of cardiotoxicity in some patients, some of them with pre-existing issues. 
 The use of organ-on-a-chip models of the heart could provide multiple advan-
tages for assessing the impact of this and other viral infections in the cardiac tissue. 
Heart-on-a-chip models that recapitulate the cardiac tissue level functionality and 
reproduce the mechanism of a human heart have been widely reported [26]. Typ-
ically, cardiomyocytes derived from human pluripotent stem cells are employed to 
line the chamber(s) of the chip. However, to make the cardiomyocytes contract syn-
chronously it is important to accurately reproduce the native cellular organization of 
the heart by exhibiting sarcomeres assembling with aligned tissue structure. For this, 
heart-on-a-chip models typically incorporate microelectrodes to stimulate the cardi-
omyocytes to obtain a better maturation, orientation and contraction. This type of 
model can contribute not only to decipher human heart functions but also to inves-
tigate diseases that affect the cardiac tissue or to screen the efficacy of drugs [27]. In 
this regard, Agarwal et al. reported a heart-on-a-chip model for the high-throughput 
study of pharmacological drugs (Figure 5) [28]. This type of assay showed numerous 
advantages compared to pharmacological studies based on isotropic layers of cardiac 
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myocytes, such as a high control over the fluid flow for injecting and washing out the 
drug. As a proof-of-concept, isoproterenol, a typical pharmacological agent used for 
the treatment of bradycardia, was injected on-chip and its effect on the contractility 
of electrically-stimulated cardiomyocytes investigated. The obtained results showed 
a dose-dependent response of the drug, which was monitored by an automatized 
contractility assay. 
 Some strategies aiming at reducing the degree of infection of COVID-19 
propose the use of angiotensin II, a novel vasopressor agent recently approved in 
US and Europe. The rationale is that exogenous angiotensin II can bind, inhibit 
and down-regulate ACE-2 and, potentially, prevent SARS-CoV-2 from entering 
the cell [29]. However, this approach may be damaging in some other organs and 
tissues, such as the heart. To investigate the potential cardiac dysfunction of angio-
tensin II (Ang II), a heart-on-a-chip model was employed recapitulating the native 
laminar cardiac tissue structure [29]. To this aim, the deflections resulting from 
contracting healthy and Ang II-treated tissues were compared, showing that treated 
cardiac tissues induced pathological gene expression profiles and arrhythmia. These 
results showed that, even though Ang II could have some beneficial effects against 
the virus in the lung, it may also be cardiotoxic. Overall, this illustrates the poten-
tial of this type of organ model to identify toxicity effects of pharmacological com-
pounds. In this regard, there is currently an intense research in the development 
of heart-on-a-chip systems interconnected with other organ models. Among them, 
the liver is an important organ to evaluate unforeseen cardiotoxic effects of drug 
metabolites. Some works have already shown that a drug per se is not toxic, but are 
their metabolites. Therefore, future organ models and drug screening applications 
must consider the use of advanced multi-organ-on-a-chip systems to evaluate this 
type of secondary toxicity. 
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Figure 5. Heart-on-a-chip. Microfluidic device based on muscular thin films (MTF) composed of cardiomy-
ocytes cultured on a deformable PDMS thin film. (A) Fabrication scheme; (B) Laser-induced manufacturing 
of the cantilevers; (C) Building blocks of the microfluidic heart-on-a-chip model; (D) Final prototype. Re-
printed with permission from the publisher [28]”  (Royal Society of Chemistry).
 
 • Kidney-on-a-chip
 Renal dysfunctions, such as acute kidney injury, are also related to viral infec-
tions. Many viruses, such as SARS-CoV-2, specially infect renal tubules in the kidney 
tissue and can be therefore a severe complication [30]. Recent evidences obtained in 
autopsies from deceased patients with COVID-19 showed not only a prominent acute 
proximal tubular injury, but also peritubular erythrocyte aggregation and glomerular 
fibrin thrombi with ischemic collapse, among other lesions [31]. These facts highlight 
that a detailed examination of kidney damage is of critical importance. Microfluid-
ics can also help in analyzing kidney abnormalities to provide important information 
for future clinical interventions. As an example, a distal tubule-on-a-chip model of vi-
rus-induced kidney disease was recently developed to explore the pathogenesis of vi-
rus-related renal dysfunction using pseudorabies virus as a test bed [32]. The model 
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successfully reproduced both the distal renal barrier structure of the native tissue and 
the sodium reabsorption function. Importantly, after viral infection, it was observed a 
renal dysfunction in electrolyte regulation that would eventually lead to virus-induced 
serum electrolyte abnormalities. Interestingly, the virus infection did not perturb the 
regulation function of Ang II in sodium reabsorption during the first hours after infec-
tion, thus providing key insights about the virus pathogenesis. It would be interesting 
to evaluate the same symptoms using SARS-CoV-2 virus due to the important role of 
Ang II on its pathogenesis.
 Kidney-on-a-chip models have also been employed to advance in the discovery 
of drugs and understanding their toxicity [33]. Similar to cardiotoxicity, nephrotoxic-
ity of anti-viral compounds is also a crucial component in drug discovery. As an exam-
ple, Musah et al., recently developed human kidney glomerulus-on-a-chip model - the 
major site of blood filtration - using podocytes derived from human induced pluripo-
tent stem cells recapitulating the native tissue-tissue interface of the human glomerulus 
in the kidney [34]. This study showed the nephrotoxicity of a common cancer drug, 
adriamycin, which illustrated the ability of this on-chip model to mimic the function 
and disease acquisition of the glomerular capillary. A similar glomerulus-on-a-chip 
model was also developed to mimic human hypertensive nephropathy, an important 
renal disease that can lead to glomerular sclerosis (scarring of the kidney blood vessels) 
[35]. The model reconstituted the cellular composition and functions of the native 
glomerulus and was used to investigate the mechanism of glomerular sclerosis caused 
by glomerular hypertension. The chip was formed by two perfused channels separated 
by a porous membrane, which was lined in the opposed layers by glomerular endothe-
lial cells and podocytes (Figure 6). The obtained results showed that glomerular me-
chanical forces were fundamental in the rearrangement of the cytoskeleton as well as 
in cell junction damage that leads to increased glomerular leakage that is observed in 
hypertensive nephropathy. Overall, this model and similar ones could provide a physi-
ologically-relevant platform for drug screening and toxicology testing, as well as for the 
evaluation of viral infections in the kidney.
 Note finally that the effect of COVID-19 on the kidney has already been inves-
tigated using other type of models, such as animal models or organoids. In the latter, it 
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was recently found that SARS-CoV-2 infection in the kidney could be prevented using 
a soluble ACE-2 receptor [36]. A similar approach could be therefore performed using 
microfluidics, which may provide additional and complementary information on the 
physiopathology of the disease as well as on the effects of therapeutic drugs. 
 
Figure 6. Kidney-on-a-chip.  (A) Scheme showing the building blocks of the functional unit of the kidney 
- the glomerulus. In the capillary loops, the glomerular filtrate penetrates the glomerular filtration barrier 
(GFB) into the Bowman´s - urine - capsule. (B) Schemes of the (left) healthy and (right) hypertensive glomer-
ulus-on-a-chip and its main constituents. The model recreated the physiological glomerular filtration by per-
fusing the upper channel and causing mechanical forces. The modulation of the mechanical forces leads to a 
pathological phenotype. (C-D) Scheme and picture of an array of glomerulus-on-a-chip models. Reprinted 
with permission from the publisher [35]. (Creative Commons Attribution 4.0 International License).
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Vasculature-on-a-chip
 Microfluidic devices and organs-on-a-chip systems can also be employed to re-
produce the human vasculature, including both the blood and lymphatic vessels [37]. 
This type of models may find important applications in the field of nanomedicine and 
drug delivery, for example,  by investigating the reduced target efficiency of drugs com-
pared to the injected dose [38]. One of the main reasons behind this limited efficiency 
is the lack of knowledge about the behavior of drugs in the vasculature. In addition to 
this, other critical events occurring during viral infections justify the need of this type 
of vasculature models. This includes the massive formation of blood clotting occur-
ring in COVID-19. Indeed, together with SARS-CoV-2-induced pneumonia, blood 
clotting is directly responsible of a large amount of deaths; and recent evidences have 
shown that blood clots arise in 20-30% of COVID-19 patients [39, 40]. The mecha-
nisms involved on this massive blood clot formation are just beginning to be investigat-
ed, but very few insights have been obtained so far. Multiple patients, including young 
healthy individuals, are dying from strokes caused by the blockages in the brain. Addi-
tionally, miniature clots have been also observed all around the body, including small 
capillaries in the lung and skin, restricting the flow of oxygenated blood [41, 42]. The 
current standard-of-care to treat this massive clotting is based on injecting systemically 
blood thinning medication (e.g., heparin or derivatives). However, these drugs are not 
capable to reliably prevent clotting in patients with COVID-19 or to dissolve them. In 
addition, a major drawback of standard anti-thrombotic medication is its toxicity, in 
particular, when injected for long period. 
 Microfluidics can contribute to gain key insights about the fundamental mech-
anisms of the massive clotting formation through the development of vasculature- or 
vessel-on-a-chip models [37]. In this regard, some microfluidic chips have already been 
developed to investigate the formation of blood clots (Figure 7). As an example, a ser-
pentine-like microfluidic channel was recently developed to mimic the native capil-
lary bed. The walls of the channel were functionalized with well-controlled concen-
trations of fibronectin, which promoted the aggregation of (porcine) red blood cells. 
This system was employed to evaluate the efficiency of clinically-used heparin and to 
assess the dynamics of clotting formation. However, the versatility of the chip gives 
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ample space to use it for testing other blood-thinning medication, or other type of 
innovative compounds aiming and preventing the formation of clots or to bust them. 
 
Figure 7. Vasculature-on-a-chip. (Left) Phase-contrast microscopy image of red blood cells flowing along a 
microfluidic channel (200 mm in diameter) and forming massive clotting. (Right) Detailed image of a blood 
clot and flow of red blood cells. Source: David Caballero.
  
 Taken together, vasculature-on-a-chip systems, despite its simplicity, may find 
important applications for the study of critical events occurring during viral infec-
tion, in particular massive blood clotting, and a drug-screening platform to test the 
efficacy of drugs.
 
BIOPRINTING AND VIRUS PANDEMICS
 Three-dimensional (3D) printing is considered as an innovative field in several 
areas, namely in tissue engineering and regenerative medicine. The 3D cell-printing 
of living tissues, called 3D bioprinting, is based on a bottom-up strategy assessing the 
construction of relevant tissues through the simultaneous deposition of bioinks, com-
posed by supportive biomaterial-based matrices containing biophysical and biochemi-
cal cues, with a single or multiple mixture of living cells. 
 During the ongoing COVID-19 world crisis, several companies specialized 
in 3D printing threw helpful initiatives to restrain the widespread of the virus [43]. 
Their solutions and efforts have been put at the service of medical staff and patients by 
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creating a myriad of 3D printed materials, from printed respirators, ventilators, and 
other medical equipment [44]. 
 Outside the hospitals, researchers and scientists are using bioprinting technol-
ogies not only to help protect medical staff and patients but also to contribute to find 
a cure to this epidemic. CLECELL©, a Korean company has developed an artificial 
tissue and created a respiratory epithelium model earlier this year using its proprietary 
3D bioprinter, the U-FAB©. What is so interesting about this model is that it is ex-
pected to become a tool to test for the severe acute respiratory syndrome coronavirus 
(SARS-Cov-2), as well as an invaluable instrument for assessing the mechanisms of this 
and other viruses [45]. According to the company, since SARS-CoV-2 is less infectious 
towards animals, this new technology is being considered as a prospective substitute to 
more traditional ones (fertilized eggs to create vaccines). Instead, CLECELL’s innova-
tive bioprinting technique has the potential to become a testbed for various viruses [44].
 Another out of the box example of scientists fighting COVID-19 is the case 
of Prellis Biologics©[45]. This bioprinting research company is studying and testing 
the potential of using synthetic bioprinted lymph nodes for the production of fully 
human antibodies for COVID-19. According to the company, the process of build-
ing the antibodies starts with bioprinting the synthetic human lymph nodes, which 
are posteriorly colonized with healthy human blood cells. The synthetic lymph nodes 
are then “vaccinated” with promising formulations after being exposed to the virus. 
In this complex process, the cells that produce the antibodies divide from non-re-
sponding cells, making it possible to isolate them. From there, antibody sequences 
can be produced in therapeutic quantities in collaboration with biotech or pharma-
ceutical companies [45].
 Many studies already published, namely in the field of 3D bioprinting in the 
area of lung and immune systems, could be potentially applicable in the future, both 
for studying the pathology of COVID-19 and accelerate the drug discovery process. 
However, the real potential to create models for viral infection studies has not yet been 
fully realized [46, 47]. In a study conducted by Berg et al. [46], it was described the 
optimization of a bioink composition for extrusion printing and a 3D model for the 
infection of Influenza A was achieved. A hydrogel mix of alginate, gelatin and Matrigel 
411
A Universidade do Minho em tempos de pandemia (Re)Ações
TISSUE ENGINEERING AND REGENERATIVE...
was used as a scaffold for the 3D arrangement of A549 human alveolar cells [46]. In-
fection of the 3D model with a seasonal Influenzas’ A strain resulted in widespread 
distribution of the virus and also a typical clustered infection, which does not happen 
in two-dimensional cell culture. The bioink supported viral replication and pro-in-
flammatory interferon release of the infected cells, therefore exhibiting a basic immune 
response by releasing the antiviral IL-29 (interferon λ1) [46]. 
 Overall, these examples show how scientists can contribute in the field of bio-
printed in vitro models of disease in order to develop a technological platform to inves-
tigate and fight COVID-19 and other future virus pandemics.
CONCLUSION
 During the last decades, different viral outbreaks have affected the population 
worldwide causing a large amount of deaths, including, among others, the MERS, 
Ebola, Zika, SARS-CoV, and more recently SARS-CoV-2. The recent history has 
demonstrated the need for innovative technological solutions capable of investigating 
the mechanism of action of these pathogens, or to evaluate in a fast and cost-effective 
manner the efficacy of anti-viral drugs for future viral outbreaks. In this regard, micro-
fluidic systems have demonstrated to be a valuable tool for the detailed investigation of 
viral infection and its treatment. Microfluidic analytical systems, together with lab- and 
organ-on-a-chip platforms can be employed to gain mechanistic insights about disease 
etiology. They can also be employed for the early diagnosis of the disease at point-of-
need locations and to screen the efficiency of drugs in native-like conditions. Overall, 
the applications of microfluidics in viral cell biology are vast, and may be considered as 
a promising clinical tool to complement current analytical technologies for the rapid 
diagnostics of pathologies, as well as for drug discovery and drug screening. Moreover, 
the future of translational human immunology is bright in many research fields and, 
in particular, in 3D bioprinting. Continuing to develop more sophisticated models of 
human immunity will improve our chances of successfully translating findings from 
fundamental biological studies to the clinic. A main goal should be to continue to 
develop tools to close the animal gap, to develop human-based systems that have the 
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advantages of animal models, including high throughput and the potential for mecha-
nistic, well-controlled studies. Strong collaborations between scientists, engineers, and 
clinicians will help to accelerate this process.
 Finally, it is worth mentioning that at the 3B´s Research Group, I3Bs from Uni-
versity of Minho, we are developing a new generation of organ-on-a-chip models for 
the study of physiopathological events and innovative bioprinted in vitro models of 
disease. We are convinced that such models will find vast applications in the clinics and 
biomedical industry in the near future due to their advanced capabilities. 
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